Product Description
TAK-816 is a conjugated Hib vaccine being tested in healthy infants aged 3-6 months at the time of the first dose. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01379846)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Subcutaneous,Intramuscular
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Influenza, Human|Haemophilus Infections|Cellulitis|Meningitis, Haemophilus|Sepsis|Epiglottitis|Tetanus|Myelitis|Arthritis, Infectious|Diphtheria|Pneumonia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| JapicCTI-142454 | P3 |
Completed |
Influenza, Human|Haemophilus Infections |
2015-09-30 |
|
| TAK-816/OCT-002 | P3 |
Completed |
Influenza, Human |
2015-03-01 |
|
| JapicCTI-111516 | P3 |
Completed |
Influenza, Human |
2013-07-31 |
|
| TAK-816/CCT-001 | P3 |
Completed |
Arthritis, Infectious|Pneumonia|Tetanus|Diphtheria|Epiglottitis|Sepsis|Meningitis, Haemophilus|Influenza, Human|Cellulitis|Myelitis |
2013-02-01 |